Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120758082> ?p ?o ?g. }
- W2120758082 endingPage "2766" @default.
- W2120758082 startingPage "2759" @default.
- W2120758082 abstract "A randomized controlled trial.To evaluate the long-term efficacy of infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-alpha), in patients with acute/subacute sciatica secondary to herniated disc.The results of experimental studies and our open-label trial support the use of infliximab in sciatica. Here we report the 1-year results of a randomized controlled trial (FIRST II, Finnish Infliximab Related STudy) evaluating the efficacy and safety of a single infusion of infliximab for sciatic pain.Inclusion criteria were unilateral sciatic pain with a disc herniation concordant with the symptoms and signs of radicular pain. Patients had to be candidates for discectomy. Criteria for discectomy included (in addition to a symptomatic disc herniation on MRI) neural entrapment (straight leg raising [SLR] < or =60 degrees ) with either a short-term (2-4 weeks) severe or long-term (4-12 weeks) moderate leg pain. Forty patients were allocated to a single intravenous infusion of either infliximab 5 mg/kg or placebo. Differences in the clinical examination parameters (straight leg raise [SLR], muscle strength, sensory defects, tendon reflexes), patient-reported symptoms (leg and back pain using a visual analog scale [VAS], Oswestry disability, quality-of-life [RAND-36]), sick leaves, number of discectomies, and adverse effects between the two treatment groups over the 1-year follow-up were compared using Mann-Whitney U test or Student's t test, repeated-measures analysis, or Cox proportional hazards model. Logistic regression was used to assess the predictors of good response.Sixty-seven percent of patients in the infliximab group reported no pain at 52 weeks compared with 63% in the control group (P = 0.72). Similar efficacy was observed between treatment groups for other outcomes. Eight patients in each group required surgery. Three nonserious adverse reactions were encountered in the infliximab group. The response (irrespective of the treatment) was significantly better with shorter symptom duration and less SLR restriction at baseline. Patients in the infliximab group appeared to especially benefit in cases of a L4-L5 (or L3-L4) herniation and if a Modic change was colocalized at the symptomatic level.Although the long-term results of this randomized trial do not support the use of infliximab compared with placebo for lumbar radicular pain in patients with disc herniation-induced sciatica, further study in a subgroup of patients with L4-L5 or L3-L4 herniations, especially in the presence of Modic changes, appears to be warranted." @default.
- W2120758082 created "2016-06-24" @default.
- W2120758082 creator A5006605579 @default.
- W2120758082 creator A5007640330 @default.
- W2120758082 creator A5007960664 @default.
- W2120758082 creator A5010697918 @default.
- W2120758082 creator A5021038015 @default.
- W2120758082 creator A5032813108 @default.
- W2120758082 creator A5033403912 @default.
- W2120758082 creator A5044634343 @default.
- W2120758082 creator A5046506011 @default.
- W2120758082 creator A5051688538 @default.
- W2120758082 creator A5056184179 @default.
- W2120758082 creator A5063301482 @default.
- W2120758082 creator A5066693323 @default.
- W2120758082 creator A5067703791 @default.
- W2120758082 creator A5074811397 @default.
- W2120758082 creator A5086421569 @default.
- W2120758082 date "2006-11-01" @default.
- W2120758082 modified "2023-10-17" @default.
- W2120758082 title "The Treatment of Disc Herniation-Induced Sciatica With Infliximab" @default.
- W2120758082 cites W1965538993 @default.
- W2120758082 cites W1966188170 @default.
- W2120758082 cites W2013217407 @default.
- W2120758082 cites W2020353352 @default.
- W2120758082 cites W2025571537 @default.
- W2120758082 cites W2030279898 @default.
- W2120758082 cites W2076854724 @default.
- W2120758082 cites W2094347820 @default.
- W2120758082 cites W2104695445 @default.
- W2120758082 cites W2121293799 @default.
- W2120758082 cites W2128759000 @default.
- W2120758082 cites W2160779124 @default.
- W2120758082 cites W2162878610 @default.
- W2120758082 cites W377849966 @default.
- W2120758082 doi "https://doi.org/10.1097/01.brs.0000245873.23876.1e" @default.
- W2120758082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17108825" @default.
- W2120758082 hasPublicationYear "2006" @default.
- W2120758082 type Work @default.
- W2120758082 sameAs 2120758082 @default.
- W2120758082 citedByCount "162" @default.
- W2120758082 countsByYear W21207580822012 @default.
- W2120758082 countsByYear W21207580822013 @default.
- W2120758082 countsByYear W21207580822014 @default.
- W2120758082 countsByYear W21207580822015 @default.
- W2120758082 countsByYear W21207580822016 @default.
- W2120758082 countsByYear W21207580822017 @default.
- W2120758082 countsByYear W21207580822018 @default.
- W2120758082 countsByYear W21207580822019 @default.
- W2120758082 countsByYear W21207580822020 @default.
- W2120758082 countsByYear W21207580822021 @default.
- W2120758082 countsByYear W21207580822022 @default.
- W2120758082 countsByYear W21207580822023 @default.
- W2120758082 crossrefType "journal-article" @default.
- W2120758082 hasAuthorship W2120758082A5006605579 @default.
- W2120758082 hasAuthorship W2120758082A5007640330 @default.
- W2120758082 hasAuthorship W2120758082A5007960664 @default.
- W2120758082 hasAuthorship W2120758082A5010697918 @default.
- W2120758082 hasAuthorship W2120758082A5021038015 @default.
- W2120758082 hasAuthorship W2120758082A5032813108 @default.
- W2120758082 hasAuthorship W2120758082A5033403912 @default.
- W2120758082 hasAuthorship W2120758082A5044634343 @default.
- W2120758082 hasAuthorship W2120758082A5046506011 @default.
- W2120758082 hasAuthorship W2120758082A5051688538 @default.
- W2120758082 hasAuthorship W2120758082A5056184179 @default.
- W2120758082 hasAuthorship W2120758082A5063301482 @default.
- W2120758082 hasAuthorship W2120758082A5066693323 @default.
- W2120758082 hasAuthorship W2120758082A5067703791 @default.
- W2120758082 hasAuthorship W2120758082A5074811397 @default.
- W2120758082 hasAuthorship W2120758082A5086421569 @default.
- W2120758082 hasConcept C126322002 @default.
- W2120758082 hasConcept C141071460 @default.
- W2120758082 hasConcept C14184104 @default.
- W2120758082 hasConcept C142724271 @default.
- W2120758082 hasConcept C168563851 @default.
- W2120758082 hasConcept C204787440 @default.
- W2120758082 hasConcept C27081682 @default.
- W2120758082 hasConcept C2776008035 @default.
- W2120758082 hasConcept C2776698514 @default.
- W2120758082 hasConcept C2777138892 @default.
- W2120758082 hasConcept C2779134260 @default.
- W2120758082 hasConcept C2779978343 @default.
- W2120758082 hasConcept C42219234 @default.
- W2120758082 hasConcept C44575665 @default.
- W2120758082 hasConcept C71924100 @default.
- W2120758082 hasConceptScore W2120758082C126322002 @default.
- W2120758082 hasConceptScore W2120758082C141071460 @default.
- W2120758082 hasConceptScore W2120758082C14184104 @default.
- W2120758082 hasConceptScore W2120758082C142724271 @default.
- W2120758082 hasConceptScore W2120758082C168563851 @default.
- W2120758082 hasConceptScore W2120758082C204787440 @default.
- W2120758082 hasConceptScore W2120758082C27081682 @default.
- W2120758082 hasConceptScore W2120758082C2776008035 @default.
- W2120758082 hasConceptScore W2120758082C2776698514 @default.
- W2120758082 hasConceptScore W2120758082C2777138892 @default.
- W2120758082 hasConceptScore W2120758082C2779134260 @default.
- W2120758082 hasConceptScore W2120758082C2779978343 @default.
- W2120758082 hasConceptScore W2120758082C42219234 @default.